Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2019 | 1 |
2021 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.
N Engl J Med. 2017.
PMID: 28296618
Free article.
Clinical Trial.
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors.
Durairaj C, Chakrabarti J, Ferrario C, Hirte HW, Babu S, Piha-Paul SA, Plotka A, Hoffman J, Shi H, Wang DD.
Durairaj C, et al.
Clin Pharmacokinet. 2021 Jul;60(7):921-930. doi: 10.1007/s40262-020-00983-y. Epub 2021 Mar 9.
Clin Pharmacokinet. 2021.
PMID: 33686631
Free PMC article.
Clinical Trial.
Primary PK parameters included the area under the plasma concentration-time curve from 0 to 24 h (AUC(0-24)) and maximum observed plasma concentration (C(max)) at steady state (Day 22). ...
Primary PK parameters included the area under the plasma concentration-time curve from 0 to 24 h (AUC(0-24)) and maximum observed pla …
Item in Clipboard
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A, Miller WH Jr, Blay JY, Gietema JA, Bang YJ, Mileshkin LR, Hirte HW, Higgins B, Blotner S, Nichols GL, Chen LC, Petry C, Yang QJ, Schmitt C, Jamois C, Siu LL.
Italiano A, et al.
Invest New Drugs. 2021 Dec;39(6):1587-1597. doi: 10.1007/s10637-021-01141-2. Epub 2021 Jun 28.
Invest New Drugs. 2021.
PMID: 34180037
Free PMC article.
Clinical Trial.
Item in Clipboard
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.
Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP.
Verheijen RB, et al.
Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.
Target Oncol. 2019.
PMID: 30742245
Free PMC article.
Clinical Trial.
The order of administration was randomized, and pharmacokinetic samples were collected for 48 h after administration of a 200 mg dose of BI 853520. Lack of effect would be demonstrated if the 90% confidence interval (CI) of the ratio of the adjusted geometric mean (GMR) of …
The order of administration was randomized, and pharmacokinetic samples were collected for 48 h after administration of a 200 mg dose …
Item in Clipboard
Cite
Cite